ArticlePloS one2013
Evaluation of paeonol skin-target delivery from its microsponge formulation: in vitro skin permeation and in vivo microdialysis.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cutaneous Pharmacokinetics of Topically Applied Novel Dermatological Formulations.AAPS PharmSciTech · 2024Review
- Microsponge based gel as a simple and valuable strategy for formulating and releasing Tazarotene in a controlled manner.Scientific reports · 2022Article
- Biological Activities of Paeonol in Cardiovascular Diseases: A Review.Molecules (Basel, Switzerland) · 2021Review
- Plant-Derived Chinese Medicine Monomers on Ovarian Cancer via the Wnt/Journal of oncology · 2021Review
- Microsponges for dermatological applications: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2020Review
- Paeonol-mediated apoptosis of hepatocellular carcinoma cells by NF-κB pathway.Oncology letters · 2019Article
- Encapsulation of babchi essential oil into microsponges: Physicochemical properties, cytotoxic evaluation and anti-microbial activity.Journal of food and drug analysis · 2019Article
- Formulation and evaluation of curcumin microsponges for oral and topical drug delivery.Progress in biomaterials · 2018Article
- Pharmacokinetic and Pharmacodynamics of Self-Assembled Cubic Liquid Crystalline Nanoparticle Gel After Transdermal Administration.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Beneficial Effects Exerted by Paeonol in the Management of Atherosclerosis.Oxidative medicine and cellular longevity · 2018Review
- Article
- Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy.Journal of basic and clinical pharmacy · 2016Article
- Self-Assembled Cubic Liquid Crystalline Nanoparticles for Transdermal Delivery of Paeonol.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Fabrication and Characterization of Sertaconazole Nitrate Microsponge as a Topical Drug Delivery System.Indian journal of pharmaceutical sciencesArticle
- Microscale Delivery Systems for Hydrophilic Active Ingredients in Functional Consumer Goods.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to design a novel topical skin-target drug-delivery system, the paeonol microsponge, and to investigate its drug-release patterns in dosage form, both in vitro and in vivo. Paeonol microsponges were prepared using the quasi-emulsion solvent-diffusion method. In vitro release studies were carried out using Franz diffusion cells, while in vivo studies were investigated by microdialysis after the paeonol microsponges were incorporated into a cream base. In vitro release studies showed that the drug delivered via microsponges increased the paeonol permeation rate. Ex vivo drug-deposition studies showed that the microsponge formulation improved drug residence in skin. In addition, in vivo microdialysis showed that the values for the area under the concentration versus time curve (AUC) for the paeonol microsponge cream was much higher than that of paeonol cream without microsponges. Maximum time (Tmax) was 220 min for paeonol microsponge cream and 480 min for paeonol cream, while the half-life (t1/2) of paeonol microsponge cream (935.1 min) was almost twice that of paeonol cream (548.6 min) in the skin (n = 3). Meanwhile, in the plasma, the AUC value for paeonol microsponge cream was half that of the paeonol cream. Based on these results, paeonol-loaded microsponge formulations could be a better alternative for treating skin disease, as the formulation increases drug bioavailability by lengthening the time of drug residence in the skin and should reduce side-effects because of the lower levels of paeonol moving into the circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.